Results 141 to 150 of about 3,015 (158)

A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, in human plasma

Journal of Pharmaceutical and Biomedical Analysis, 2016
Amedeo De Nicolò, Lucio Boglione, Chiara Simona Cardellino   +2 more
exaly  

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial

Journal of Hepatology, 2014
Namiki Izumi
exaly  

Sofosbuvir/simeprevir

Reactions Weekly, 2015
openaire   +1 more source

Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial

Gastroenterology, 2014
Thomas Berg, Graham R Foster, Michael W Fried   +2 more
exaly  

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies

Journal of Hepatology, 2015
Thierry Verbinnen, Leen Vijgen, Hugo Ceulemans   +2 more
exaly  

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

Hepatology, 2015
Michael D Leise, Kymberly D Watt, Ryan Mclemore   +2 more
exaly  

Simeprevir/sofosbuvir

Reactions Weekly, 2018
openaire   +1 more source

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

Clinical Pharmacokinetics, 2015
Jan Snoeys
exaly  

Simeprevir/sofosbuvir

Reactions Weekly, 2019
openaire   +1 more source

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis

Hepatology, 2015
exaly